Regencell Bioscience Holdings (RGC) Assets (2020 - 2025)

Regencell Bioscience Holdings (RGC) posted Assets of $3.0 million for Q4 2025, down 47.64% on a QoQ basis from $5.8 million in Q2 2025.

Regencell Bioscience Holdings (RGC) Assets (2020 - 2025) Analysis & Trends

Regencell Bioscience Holdings' Assets history runs 3 years deep, the most recent figure standing at $3.0 million for Q4 2025.

Quarterly Assets changed N/A year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.8 million (changed N/A YoY) and the FY2025 annual result came in at $5.8 million, changed N/A from the prior year.
Assets was $3.0 million for Q4 2025 at Regencell Bioscience Holdings, down from $5.8 million in the prior quarter.
Across five years, Assets topped out at $12.6 million in Q2 2023 and bottomed at $3.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	43.40 Bn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	40.04 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	15.15 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	98.91 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	6.71 Bn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	69.30 Bn
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	36.83 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	4.91 Bn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	13.22 Bn
10	Regencell Bioscience Holdings	2.78 Bn	2.78 Bn	-	3.01 Mn

Download Data